Source - LSE Regulatory
RNS Number : 5241Q
Creo Medical Group PLC
31 May 2024
 




Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

Posting of 2023 Annual Report and Accounts

and

Notice of Annual General Meeting

 

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, announces that the Annual Report and Accounts for the year ended 31 December 2023 and the Notice of the Company's Annual General Meeting ("AGM") have now been published on the Company's website at https://www.creomedical.com/en/investors/reports-and-presentations, with hard copies being posted to those shareholders who have not elected to receive electronic communication from the Company.

 

The AGM will be held on Wednesday, 26 June 2024 at 10:00am at Creo House, Beaufort Park, Beaufort Park Way, Chepstow NP16 5UH and will consider the Resolutions set out in the Notice of AGM. The Company's CEO, Craig Gulliford, will make a short presentation at the meeting. No new material information will be included within the presentation.

 

Shareholders are encouraged to vote by proxy at the AGM, which can be done:

 

·    by completing, signing the Form of Proxy and returning it to Equiniti; or

·    in the case of CREST members, by utilising the CREST electronic proxy appointment service.

 

Proxy votes must be received no later than 10:00am on 24 June 2024. Shareholders are recommended to appoint the Chair of the meeting as their proxy rather than a named person, as any such other person may not be permitted to attend the AGM in the event of unforeseen circumstances (e.g. illness).

 

Voting will be conducted on each Resolution by way of a poll.

 

Enquiries:

Creo Medical Group plc

www.creomedical.com

Richard Rees (CFO)

+44 (0)1291 606 005



Cavendish Capital Markets Limited

+44 (0)20 7397 8900

Stephen Keys / Camilla Hume (NOMAD)


Michael Johnson (Sales)




Deutsche Numis (Joint Broker)

Freddie Barnfield / Duncan Monteith / Euan Brown

+44 (0)20 7260 1000



Walbrook PR

Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com

Paul McManus / Sam Allen

Phillip Marriage

Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258

+44 (0)7867 984 082 

 

About Creo Medical 

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSWPUWGAUPCGAU
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Creo Medical Group PLC (CREO)

-0.25p (-1.30%)
delayed 13:30PM
JavaScript chart by amCharts 3.4.4